STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Caribou Biosciences (NASDAQ: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that its President and CEO, Rachel Haurwitz, PhD, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference. The presentation is scheduled for May 13th at 2:35 PM PDT. The webcast will be accessible through Caribou's website and will remain available for at least 30 days following the event.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 13th at 2:35 PM PDT.

For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for at least 30 days after the event.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is focused on CB-010 and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Follow us @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com

Media:
Peggy Vorwald, PhD
media@cariboubio.com


FAQ

When is Caribou Biosciences (CRBU) presenting at the BofA Securities Health Care Conference 2025?

Caribou Biosciences will present at the BofA Securities Health Care Conference on May 13th, 2025, at 2:35 PM PDT.

Who will represent Caribou Biosciences (CRBU) at the BofA Securities conference?

Rachel Haurwitz, PhD, who serves as Caribou's president and chief executive officer, will represent the company in a fireside chat.

How long will the CRBU conference webcast be available for viewing?

The webcast will be available on Caribou's website for at least 30 days after the event.

What type of company is Caribou Biosciences (CRBU)?

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company.
Caribou Biosciences, Inc.

NASDAQ:CRBU

CRBU Rankings

CRBU Latest News

CRBU Latest SEC Filings

CRBU Stock Data

174.79M
83.54M
9.82%
42.39%
4.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BERKELEY